Cargando…

Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia

BACKGROUND: The BELA and BFORE trials compared bosutinib starting doses of 500 mg once daily (QD) and 400 mg QD, respectively, with imatinib in adults with newly diagnosed chronic phase chronic myeloid leukemia (CP‐CML). The B1871048 trial evaluated bosutinib 400 mg QD in Japanese patients with newl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garrett, May, Knight, Beverly, Cortes, Jorge E., Deininger, Michael W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524044/ https://www.ncbi.nlm.nih.gov/pubmed/37553873 http://dx.doi.org/10.1002/cam4.6439

Ejemplares similares

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
por: Brümmendorf, Tim H., et al.
Publicado: (2022)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
por: Cortes, Jorge E., et al.
Publicado: (2018)

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
por: Cortes, Jorge E., et al.
Publicado: (2018)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
por: Brümmendorf, Tim H, et al.
Publicado: (2015)

Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
por: Ono, Takaaki, et al.
Publicado: (2022)

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
por: Isfort, Susanne, et al.
Publicado: (2018)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
por: Muresan, B., et al.
Publicado: (2021)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
por: Mita, Akiko, et al.
Publicado: (2018)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013)

Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects
por: Ault, Patricia S., et al.
Publicado: (2016)

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
por: Brümmendorf, Tim H., et al.
Publicado: (2020)

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
por: Isfort, Susanne, et al.
Publicado: (2023)

Pregnancy outcomes in patients treated with bosutinib
por: Cortes, Jorge E, et al.
Publicado: (2020)

P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA
por: Brivio, Erica, et al.
Publicado: (2023)

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2018)

Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase
por: Takatsuka, Ibuki, et al.
Publicado: (2022)

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
por: Khoury, H J, et al.
Publicado: (2018)

High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib
por: Takakuwa, Teruhito, et al.
Publicado: (2021)

Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
por: Réa, Delphine, et al.
Publicado: (2023)

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
por: Abumiya, Maiko, et al.
Publicado: (2021)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
por: Ibrahim, Ali, et al.
Publicado: (2022)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
por: Gullaksen, Stein-Erik, et al.
Publicado: (2017)

The Cytogenetic Landscape of Pediatric Chronic Myeloid Leukemia Diagnosed in Chronic Phase
por: Karow, Axel, et al.
Publicado: (2022)

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
por: Lin, Swan, et al.
Publicado: (2020)

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
por: Togasaki, E, et al.
Publicado: (2017)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

Long-term outcome of tyrosine kinase inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase
por: Zheng, Yong-Zhi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ie5ft1mggjemf1ol332u0k5fv